OBJECTIVE: PhytoSERM is a formulation of genistein, daidzein, and S-equol that has an 83-fold selective affinity for estrogen receptor-β (ERβ); and may enhance neuron function and estrogenic mechanisms in the brain without having peripheral estrogenic activity. METHODS: We conducted an overarching, two-stage, dose-ranging, double-blinded, randomized, placebo-controlled trial of 12 weeks duration comparing 50 and 100 mg/d of phytoSERM with placebo for noncognitively impaired, perimenopausal women aged 45 to 60, with intact uteri and ovaries, with at least one cognitive complaint, and one vasomotor-related symptom. Primary objectives were to assess safety and tolerability of a 50 and 100 mg daily dose; and, secondly, to evaluate potential indicators of efficacy on cognition and vasomotor symptoms over 4 and 12 weeks, and using an embedded, 4-week, 2-period, placebo-controlled crossover trial for a subset of participants. RESULTS:Seventy-one women were randomized to treatment; 70 were evaluated at 4 weeks; 12 were entered into the crossover study; 5 did not complete 12 weeks. Reasons for discontinuation were withdrawal of consent (n = 1) and lost to follow-up (n = 4). Adverse events occurred in 16.7% (n = 4) placebo, 39.1% (n = 9) 50 mg/d, and 29.2% (n = 7) 100 mg/d treated participants; 85% were mild and none was severe. Vaginal bleeding occurred in 0, placebo; 1, 50 mg; and 3, 100 mg/d participants. CONCLUSIONS: The phytoSERM formulation was well tolerated at 50 and 100 mg daily doses. Based on safety outcomes, vaginal bleeding at the 100 mg dose, and vasomotor symptoms and cognitive outcomes at 12 weeks, a daily dose of 50 mg was considered preferable for a phase 2 efficacy trial.
RCT Entities:
OBJECTIVE:PhytoSERM is a formulation of genistein, daidzein, and S-equol that has an 83-fold selective affinity for estrogen receptor-β (ERβ); and may enhance neuron function and estrogenic mechanisms in the brain without having peripheral estrogenic activity. METHODS: We conducted an overarching, two-stage, dose-ranging, double-blinded, randomized, placebo-controlled trial of 12 weeks duration comparing 50 and 100 mg/d of phytoSERM with placebo for noncognitively impaired, perimenopausal women aged 45 to 60, with intact uteri and ovaries, with at least one cognitive complaint, and one vasomotor-related symptom. Primary objectives were to assess safety and tolerability of a 50 and 100 mg daily dose; and, secondly, to evaluate potential indicators of efficacy on cognition and vasomotor symptoms over 4 and 12 weeks, and using an embedded, 4-week, 2-period, placebo-controlled crossover trial for a subset of participants. RESULTS: Seventy-one women were randomized to treatment; 70 were evaluated at 4 weeks; 12 were entered into the crossover study; 5 did not complete 12 weeks. Reasons for discontinuation were withdrawal of consent (n = 1) and lost to follow-up (n = 4). Adverse events occurred in 16.7% (n = 4) placebo, 39.1% (n = 9) 50 mg/d, and 29.2% (n = 7) 100 mg/d treated participants; 85% were mild and none was severe. Vaginal bleeding occurred in 0, placebo; 1, 50 mg; and 3, 100 mg/d participants. CONCLUSIONS: The phytoSERM formulation was well tolerated at 50 and 100 mg daily doses. Based on safety outcomes, vaginal bleeding at the 100 mg dose, and vasomotor symptoms and cognitive outcomes at 12 weeks, a daily dose of 50 mg was considered preferable for a phase 2 efficacy trial.
Authors: Gail A Greendale; Mei-Hua Huang; Katherine Leung; Sybil L Crawford; Ellen B Gold; Richard Wight; Elaine Waetjen; Arun S Karlamangla Journal: Menopause Date: 2012-08 Impact factor: 2.953
Authors: K D Setchell; N M Brown; P Desai; L Zimmer-Nechemias; B E Wolfe; W T Brashear; A S Kirschner; A Cassidy; J E Heubi Journal: J Nutr Date: 2001-04 Impact factor: 4.798
Authors: Kenneth D R Setchell; Marian S Faughnan; Tony Avades; Linda Zimmer-Nechemias; Nadine M Brown; Brian E Wolfe; Wayne T Brashear; Panjak Desai; Mark F Oldfield; Nigel P Botting; Aedin Cassidy Journal: Am J Clin Nutr Date: 2003-02 Impact factor: 7.045
Authors: David F Archer; Caroline M Dupont; Ginger D Constantine; James H Pickar; Sophie Olivier Journal: Am J Obstet Gynecol Date: 2009-01-24 Impact factor: 8.661
Authors: Kejal Kantarci; Nirubol Tosakulwong; Timothy G Lesnick; Samantha M Zuk; Val J Lowe; Julie A Fields; Jeffrey L Gunter; Matthew L Senjem; Megan L Settell; Carey E Gleason; Lynne T Shuster; Kent R Bailey; N Maritza Dowling; Sanjay Asthana; Clifford R Jack; Walter A Rocca; Virginia M Miller Journal: Neurology Date: 2018-03-21 Impact factor: 9.910
Authors: Mohammed M Alshehri; Javad Sharifi-Rad; Jesús Herrera-Bravo; Evelyn L Jara; Luis A Salazar; Dorota Kregiel; Yadav Uprety; Muhammad Akram; Mehwish Iqbal; Miquel Martorell; Margalida Torrens-Mas; Daniel Gabriel Pons; Sevgi Durna Daştan; Natália Cruz-Martins; Fethi Ahmet Ozdemir; Manoj Kumar; William C Cho Journal: Oxid Med Cell Longev Date: 2021-09-09 Impact factor: 6.543